A Phase I, Open-Label, Randomized, Single-Center, Parallel Design Study Evaluating Pharmacokinetics of CaPre (Omega-3 Phospholipid) Following Single and Multiple Oral Doses in Healthy Volunteers
Latest Information Update: 15 Nov 2019
At a glance
- Drugs Omega-3 phospholipid (Primary)
- Indications Hypertriglyceridaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Acasti Pharma
- 07 Nov 2019 Results presented in an Acasti Pharma Media Release.
- 31 Oct 2019 Results of Evaluation of OM3-PL/FFA Pharmacokinetics After Single and Multiple Oral Doses in Healthy Volunteers has published in the Clinical Therapeutics
- 22 Aug 2017 New trial record